Gated and Non-Gated Dynamic PET/CT Imaging

February 23, 2024 updated by: Washington University School of Medicine

An Exploration of Gated and Non-Gated Dynamic PET/CT Imaging

The goal of this study is to see how the images collected during the first hour compare with the routine images collected as part of the clinical scan.

Study Overview

Status

Recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Richard L Wahl, M.D.
  • Phone Number: 314-362-7100
  • Email: rwahl@wustl.edu

Study Locations

    • Missouri
      • Saint Louis, Missouri, United States, 63110
        • Recruiting
        • Washington University School of Medicine
        • Sub-Investigator:
          • Tyler J Fraum, M.D.
        • Contact:
        • Principal Investigator:
          • Richard L Wahl, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria Main Cohort:

  • 18 years of age or older
  • Scheduled to undergo a clinical PET/CT scan with any clinically prescribed radiotracer for known or suspected malignancy (pathologic confirmation not required)
  • Able to provide informed consent

Inclusion Criteria Repeatability Cohort:

  • 18 years of age or older
  • Scheduled to undergo a clinical PET/CT FDG or 68Ga- DOTA-0-Tyr3-Octreotate (DOTATATE) for known or suspected malignancy (pathologic confirmation not required)
  • Able to provide informed consent

Exclusion Criteria:

-Younger than 18 years of age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dynamic PET Imaging
  • Dynamic PET/CT imaging will begin at approximately the same time as the clinically prescribed radiotracer injection and will continue until approximately the start of the clinical scan
  • A subset of patients (up to 30 scheduled to undergo FDG or DOTATATE PET/CT imaging) will be asked to return within 7 days for a repeat imaging study.
-Will take approximately 60 minutes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of rapid, whole-body dynamic PET imaging as measured by number of participants who successfully complete the study imaging component
Time Frame: Completion of imaging for all participants enrolled in the study (estimated to be 4 years)
-Successful completion of the study imaging component will be defined as: (1) patient remains on scanner for the full dynamic phase of PET imaging prior to the standard of care PET/CT and (2) automated scanner software is able to successfully generate valid parametric maps (requires at least three consecutive whole-body PET acquisitions without substantial motion between acquisitions).
Completion of imaging for all participants enrolled in the study (estimated to be 4 years)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quantitative impacts of data motion correction (OncoFreeze) as measured by semi-quantitative standardized uptake value (SUV) metrics
Time Frame: At the time of scan (Day 1)
  • Will be assessed by comparing motion-corrected images derived from OncoFreeze with standard static non-gated PET images and conventionally gated PET images.
  • OncoFreeze is a novel approach to PET motion correction that utilizes 100% of events, which are corrected to an optimal gate image utilizing an optical flow algorithm, creating the potential for motion corrected images without increasing image noise.
  • Two independent readers blinded to the reconstruction approach will score image quality utilizing a standard Likert-type scale and will extract quantitative metrics for any apparent FDG-avid lesions.
At the time of scan (Day 1)
Clinical impacts of data motion correction (OncoFreeze) as measured by number of detectable lesions
Time Frame: At the time of scan (Day 1)
  • Will be assessed by comparing motion-corrected images derived from OncoFreeze with standard static non-gated PET images and conventionally gated PET images.
  • OncoFreeze is a novel approach to PET motion correction that utilizes 100% of events, which are corrected to an optimal gate image utilizing an optical flow algorithm, creating the potential for motion corrected images without increasing image noise.
At the time of scan (Day 1)
Repeatability of dynamic imaging as measured by calculating the measurement agreement in semi-quantitative PET metrics between test and retest dynamic images
Time Frame: Day 1 and approximately 1 week later
-Imaging metric agreement will be measured using Bland-Altman analysis. Groupwise differences between imaging time-points will also be assessed using t-tests or Mann-Whitney U tests, depending on normality.
Day 1 and approximately 1 week later
Metabolic rate of images
Time Frame: At the time of scan (Day 1)
-Will help to determine the optimal post-injection time period for dynamic PET imaging for Patlak analysis.
At the time of scan (Day 1)
Volume of distribution (intercept) images
Time Frame: At the time of scan (Day 1)
-Will help to determine the optimal post-injection time period for dynamic PET imaging for Patlak analysis.
At the time of scan (Day 1)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Richard L Wahl, M.D., Washington University School of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 29, 2020

Primary Completion (Actual)

April 10, 2023

Study Completion (Estimated)

May 31, 2024

Study Registration Dates

First Submitted

February 20, 2020

First Submitted That Met QC Criteria

February 24, 2020

First Posted (Actual)

February 25, 2020

Study Record Updates

Last Update Posted (Actual)

February 28, 2024

Last Update Submitted That Met QC Criteria

February 23, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 201910076

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The investigators may share your images with other researchers. They may be doing research in areas similar to this research or in other unrelated areas. These researchers may be at Washington University, at other research centers and institutions, or industry sponsors of research. The investigators may also share your research data with large data repositories (a repository is a database of information) for broad sharing with the research community. If the individual research data is placed in one of these repositories only qualified researchers, who have received prior approval from individuals that monitor the use of the data, will be able to look at the information.

IPD Sharing Time Frame

Beginning 3 months and ending 10 years following article publication.

IPD Sharing Access Criteria

Proposals should be directly submitted to rwahl@wustl.edu.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dynamic PET/CT Imaging

Clinical Trials on Dynamic PET/CT Imaging

3
Subscribe